Bringing a Medicine to Market in Ethiopia: A Step-by-Step Guide to EFDA Marketing Authorization
No medicine — including vaccines — may be manufactured, imported, distributed, or sold in Ethiopia without registration and a valid marketing authorization from the Ethiopian Food and Drug Authority (EFDA). This requirement, set out in the Food and Medicine Administration Proclamation No. 1112/2019, is the gateway to the Ethiopian market. For pharmaceutical manufacturers, importers, and their local agents, navigating it efficiently is the difference between a timely launch and months of avoidable delay.
There has never been a better moment to understand this process. In September 2025, the World Health Organization recognized EFDA as having achieved Maturity Level 3 (ML3) — confirming that Ethiopia now has a stable, well-functioning regulatory system for medicines. For applicants, ML3 signals a more predictable, internationally aligned process, and it reinforces the faster pathways available to products already approved by trusted regulators abroad.
This guide outlines the marketing authorization process from start to finish: who can apply, the routes available, what the dossier must contain, how the review works, and the practical points where applications most often run into trouble.
The legal framework
The process is governed by Proclamation No. 1112/2019 and operationalized in detail by the Medicine Marketing Authorization Directive No. 963/2023. Under the Proclamation, EFDA registers and authorizes a medicine by assessing its safety, quality, and efficacy through dossier evaluation, inspecting the manufacturer for GMP compliance, and, where appropriate, conducting laboratory testing on product samples. No product reaches the market without clearing these gates.
It is worth understanding two related but distinct approvals:
Marketing authorization is product-specific — permission to market a particular medicine.
A Certificate of Competence (CoC) is establishment-specific — the license every manufacturer, importer, and distributor must hold to operate at all.
A foreign manufacturer bringing a product to Ethiopia engages with both: marketing authorization for the product, and a relationship with a CoC-licensed local importer to bring it in and distribute it.
Who can apply — and the role of the local agent
An applicant for registration must hold (or work through someone who holds) the Certificate of Competence to act as a licensed importer. Critically, the applicant must also have an agency agreement with the manufacturer — one under which the local agent takes responsibility for handling quality defects, including product recall.
This makes the choice of local agent one of the most consequential decisions in market entry. The agent becomes the manufacturer's regulatory face in Ethiopia: responsible for the application, for ongoing compliance once the product is registered, for the regulatory dialogue with EFDA, and — under the agency agreement — for recall and quality-defect liability. The contractual terms between manufacturer and agent (responsibilities, liability, ownership of the registration, and what happens if the relationship ends) should be settled carefully at the outset. Getting this relationship wrong is one of the most consequential and least appreciated risks in market entry.
The four registration pathways — not every product takes the same road
This is the single most important strategic point in the entire process, and it is where specialist knowledge saves the most time and money. EFDA does not evaluate every product the same way. There are four registration routes, differing in the depth of evaluation, the requirements, and the time involved:
1. Standard. The full path: complete dossier evaluation plus GMP inspection of the manufacturing site. This applies to any product that does not qualify for one of the faster routes.
2. Reliance on stringent regulators (and WHO prequalification). For products manufactured by sites already approved and inspected by a recognized stringent regulatory authority — or products that are WHO-prequalified — EFDA waives the GMP site inspection and relies on that prior approval, while still conducting a full dossier evaluation. The applicant submits the foreign GMP certificate and the marketing authorization from the reference country. This is the route that most benefits multinational manufacturers, and ML3 status is precisely about strengthening these reliance mechanisms.
3. Fast-track. Reserved for priority products — those addressing major public health burdens or facing limited supplier availability. Historically this has covered categories such as antimalarials, antiretrovirals, anti-TB medicines, maternal and child health products, anti-cancer drugs, vaccines, and medicines for emergencies. Fast-track applications receive evaluation priority to shorten time-to-market.
4. Low-risk (risk-based). A newer, risk-based route for well-established products — known molecules with a long safety record, in conventional dosage forms (oral solids, liquids, topicals), including many OTC medicines. These receive a partial dossier review focused on administrative requirements, product information, specifications, and stability, rather than a full assessment.
In practice, a new application is screened first for fast-track eligibility, then for reliance/WHO-PQ eligibility, and only otherwise defaults to the standard full-evaluation-plus-inspection route. Identifying at the outset which route a product qualifies for is one of the highest-value strategic decisions in planning a submission — it can be the difference between weeks and many months.
What the dossier must contain
Submissions are made electronically through EFDA's regulatory information system. Under Directive No. 963/2023, the applicant must demonstrate the product's quality, safety, and efficacy, supported by:
Evidence of quality, safety, and efficacy — appropriate study data for the product.
A valid GMP compliance certificate for the manufacturing site, issued by the regulator in the country of origin (and, where relevant, other regulators).
Evidence of marketing authorization in the country of origin (and, as needed, other countries).
For a new medicine — chemical characterization of the active pharmaceutical ingredient, full manufacturing and control (CMC) data, and, as necessary, preclinical and clinical studies.
For vaccines and other biologically-manufactured medicines — documentation determined according to the specific nature of the product, reflecting the additional requirements biologics carry.
The full technical dossier follows the internationally familiar multi-module structure (broadly, the Common Technical Document format).
A practical note on labeling. A valid authorization binds the product to its approved label, including the manufacturer's name and address and the product's details. Labeling and artwork deficiencies are among the most common — and most avoidable — causes of delay. Reviewing artwork against the requirements before submission saves weeks.
How the review works
Once submitted, an application moves through several stages:
Pre-screening. A first check for completeness and administrative compliance. Incomplete or incorrect submissions are returned to the applicant at this stage — before substantive review even begins. This is the easiest place to lose time, and the easiest to get right with disciplined preparation.
Technical evaluation. The dossier is assessed on its merits, typically by a primary and then a secondary assessor, with a team leader and director verifying the outcome. During this stage EFDA commonly issues queries — requests for clarification, additional data, or correction of deficiencies. How promptly and completely the applicant responds is frequently the single biggest determinant of the overall timeline; each incomplete response effectively resets the clock.
Sample testing. After documentary approval, product samples are tested against quality specifications using reference standards.
Decision. If the Authority is satisfied on all fronts, marketing authorization is granted. Authorizations are time-limited — for products on the reliance route, validity is typically tied to the end date of the foreign quality certificate; for GMP-inspected manufacturers, authorizations run for a defined multi-year term and must then be renewed.
Where applications stall — and how to avoid it
In practice, the delays that frustrate applicants are rarely about the merits of the product. They are about preparation and process. The recurring causes, drawn from how the system actually operates:
Incomplete or disorganized dossiers that fail pre-screening and never reach substantive review on the first pass — by far the most common cause.
Slow or incomplete responses to EFDA's queries, which reset the clock each time.
Labeling and artwork deficiencies requiring resubmission.
Gaps in GMP or country-of-origin documentation.
Taking the wrong route — travelling the full standard path when the product qualified for reliance, WHO-PQ, or fast-track all along.
An under-prepared local agent unable to manage the technical back-and-forth with the Authority.
It is also worth being realistic about system-level constraints outside any single application: EFDA manages assessor capacity limits, and applicants occasionally encounter customs and foreign-exchange friction at the import stage. A well-prepared applicant cannot eliminate these, but a clean, complete, correctly-routed submission is the surest way to move through the process as quickly as the system allows.
How we can help
Prime Law advises pharmaceutical manufacturers, importers, and local agents through every stage of EFDA marketing authorization — from structuring the local agent relationship and determining which registration route a product qualifies for, to preparing and reviewing the dossier, managing the regulatory dialogue with the Authority, and handling renewals. Our founding partners helped shape the regulatory framework that governs this process, which means we understand not only what the rules require, but why they are written as they are and how they are applied in practice.
If you are planning to bring a pharmaceutical product to the Ethiopian market, write to us at info@primelaw.law.
_____________
This article is provided for general information only and does not constitute legal advice. Regulatory requirements and procedures may change; for advice on a specific product or application, please consult qualified legal counsel.
